This report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the world's leading healthcare companies.
In-depth understanding of biomarker deal trends since 2014
Access to headline, upfront, milestone and royalty data
Analysis of the structure of biomarker agreements with numerous real life case studies
Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
Access to most active biomarker dealmakers since 2014
Insight into the terms included in a biomarker agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest Biomarker agreements announced in the healthcare sectors. The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.
The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This - Chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.
One of the key highlights of the report is that over 450 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.
Analyzing actual contract agreements allows assessment of the following:
What are the precise biomarker rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
A*STAR Agency for Science
Technology and Research
A*STAR Bioprocessing Technology Institute
Abramson Cancer Center
Academic Medical Center
Accu Reference Medical Laboratory
Aelan Cell Technologies
Air Force Research Laboratory
Akili Interactive Labs
Albert Einstein College of Medicine
ALS Finding a Cure Foundation
Alzheimer's Drug Discovery Foundation
Alzheimers Research UK
American Association for Cancer Research
American Association of Neuromuscular & Electrodiagnostic Medicine
American Diabetes Association
Anavex Life Sciences
Applied DNA Sciences
Association for Frontotemporal Degeneration
Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
Austrian Institute of Technology
Avera Heart Hospital of South Dakota
Aviana Molecular Technologies
Baylor College of Medicine
Beth Israel Deaconess Medical Center
BGI Tech Solutions
Bill and Melinda Gates Foundation
Biomedical Catalyst Fund (UK)
Bonnie J. Addario Lung Cancer Foundation
Brain Biomarker Solutions in Gothenburg
Brigham and Women's Hospital
Buck Institute for Age Research
California Stem Cell
Cambridge Isotope Laboratories
CANbridge Life Sciences
Cancer Immunotherapy Trials Network
Cancer Research Institute
Cancer Research UK
Caris Life Sciences
Carolinas Medical Center (CMC)
Case Western Reserve University
Catalyn Medical Technologies
Catholic University Leuven
Cedars-Sinai Medical Center
Center for Biomarker Research in Medicine
Center for Human Immunology
Autoimmunity and Inflammation
Centers for Disease Control and Prevention
Centre for Drug Research and Development (CDRD)
Centre for Imaging Technology Commercialization
Centre Hospital University - Bordeaux
Centre Leon Berard
Centre National de la Recherche Scientifique
Children's Hospital Boston
Children's Medical Research Institute
Children's Research Institute
Children's Hospital Colorado
Christian Doppler Research Association
Cincinnati Children's Hospital Medical Center
Cohen Veterans Bioscience
Crohn's and Colitis Foundation of America
Dana-Farber Cancer Institute
Danish Center for Strategic Research into Type 2 Diabetes